Government Partnerships & Procurement

Contracts & Certifications

NRx Defense Systems works directly with DoD, VA, and federal health agencies through established procurement pathways to deliver clinically validated mental health technology to the warfighter.

Institutional Partnerships

Validated by the Institutions That Matter

DARPA

Defense Advanced Research Projects Agency

Active collaboration under the SPARC program — Surmounting Obstacles in PTSD using Refined Closed-loop feedback — contracting fMRI-guided robotic TMS for treatment-resistant combat PTSD and MDD.

Federal Research Partner

Harvard McLean Hospital

McLean Hospital, Harvard Medical School Affiliate

Clinical research partnership anchoring the TMS Service and providing academic validation for the NRx neuroplastic treatment protocol. CMO serves as Medical Director of the McLean TMS Service.

Academic Medical Partner

HOPE Therapeutics

HOPE Therapeutics

Strategic clinical partner supporting deployment of the NRx platform for active-duty and veteran populations, with a focus on rapid return-to-duty outcomes.

Clinical Deployment Partner

Department of Defense

U.S. Department of Defense

NRx technology is designed and validated for DoD clinical environments, with leadership holding active DoD advisory and research credentials including OSD and NDU senior executive service.

Primary End-User Agency

Department of Veterans Affairs

U.S. Department of Veterans Affairs

The NRx platform addresses the VA's most critical treatment-resistant mental health burden — depression, PTSD, and suicidality — with a protocol designed for integration into VA clinical workflows.

Primary End-User Agency

Regulatory & Clinical Status

Clinical Credentials & Regulatory Standing

TMS Platform

FDA-Cleared

Transcranial Magnetic Stimulation is FDA-cleared for major depressive disorder. The NRx platform employs robotically controlled, fMRI-guided TMS delivery for sub-millimeter targeting precision.

Neuroplastic Medication

FDA-Investigational

The neuroplastic medication component of the NRx protocol is currently under FDA investigational status, administered under clinical trial protocols to enhance synaptogenesis in conjunction with TMS.

fMRI Neuronavigation

Clinical Standard

Functional MRI-guided neuronavigation is an established clinical imaging modality. NRx integrates fMRI to identify malfunctioning brain centers prior to TMS targeting — a precision step not present in standard TMS protocols.

DARPA SPARC-TMS Trial

Enrollment Starts October 2026

Ongoing DARPA-contracted clinical trial evaluating the combined fMRI + robotic TMS + neuroplastic medication protocol for treatment-resistant PTSD and MDD in military populations.

Procurement Pathways

How to Engage NRx Defense Systems

NRx Defense Systems supports federal acquisition through multiple established contracting vehicles. Our leadership team holds deep experience navigating DoD and VA procurement environments.

Direct Contract

Engage NRx directly for clinical technology deployment, research collaboration, or program integration. Our team works with contracting officers to structure agreements aligned with federal acquisition regulations.

Research Collaboration

Partner with NRx under a Cooperative Research and Development Agreement (CRADA), Other Transaction Authority (OTA), or sponsored research arrangement through an affiliated academic medical center.

Clinical Pilot Program

Deploy the NRx platform at a DoD or VA clinical site under a structured pilot program with defined outcome metrics, return-to-duty tracking, and clinical oversight by NRx medical staff.

GSA Schedule & IDIQ

NRx is available to support acquisition through existing federal schedule vehicles. Contact our contracts team to discuss applicable NAICS codes, schedule alignment, and task order structuring.

Leadership Credentials

A Team Built for Federal Engagement

Jonathan C. Javitt, MD, MPH

Chairman

Architect of Executive Order 13335 (National Health IT); post-9/11 OSD appointment; drug development partnerships with Merck, Allergan, Novartis, and Pfizer; cited by more than 35,000 scientists; Johns Hopkins Adjunct Professor.

CAPT Dennis K. McBride, USN, Ret.

President

SES-4, National Defense University and Office of the Secretary of Defense, Ret.; DARPA program experience; Potomac Institute for Policy Studies President Emeritus; Georgetown Medical School Adjunct Professor.

Prof. Joshua Brown, MD, PhD

Chief Medical Officer & Principal Investigator

Chairman, Department of Psychiatry, Arizona State University; Medical Director, McLean Hospital TMS Service; $20M+ in NIMH and DARPA funding; Harvard Medical School Assistant Professor; President, Clinical TMS Society.

Ready to Explore a Partnership?

Contact our contracts and partnerships team to discuss procurement pathways, clinical deployment, or research collaboration.